Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer

被引：104

作者：

Ahmadzada T. ^{[1
]}

Reid G. ^{[1
,2
]}

McKenzie D.R. ^{[3
]}

机构：

[1] Sydney Medical School, The University of Sydney, Sydney

[2] Asbestos Diseases Research Institute (ADRI), Sydney

[3] School of Physics, The University of Sydney, Sydney

来源：

Biophysical Reviews | 2018年 / 10卷 / 1期

关键词：

Breast cancer; Cellular transport; Delivery; MicroRNA; Nanoparticles; siRNA;

D O I：

10.1007/s12551-017-0392-1

中图分类号：

学科分类号：

摘要：

Gene silencing via RNA interference (RNAi) is rapidly evolving as a personalized approach to cancer treatment. The effector molecules—small interfering RNAs (siRNAs) and microRNAs (miRNAs)—can be used to silence or “switch off” specific cancer genes. Currently, the main barrier to implementing siRNA- and miRNA-based therapies in clinical practice is the lack of an effective delivery system that can protect the RNA molecules from nuclease degradation, deliver to them to tumor tissue, and release them into the cytoplasm of the target cancer cells, all without inducing adverse effects. Here, we review the fundamentals of RNAi, cell membrane transport pathways, and factors that affect intracellular delivery. We discuss the advantages and disadvantages of the various types of nanoparticle delivery systems, with a focus on those that have been investigated in breast cancer in vivo. © 2018, International Union for Pure and Applied Biophysics (IUPAB) and Springer-Verlag GmbH Germany, part of Springer Nature.

引用

页码：69 / 86

页数：17

共 132 条

[1]

Ahmad A., Mondal S.K., Mukhopadhyay D., Banerjee R., Alkharfy K.M., Development of liposomal formulation for delivering anticancer drug to breast cancer stem-cell-like cells and its pharmacokinetics in an animal model, Mol Pharm, 13, 3, pp. 1081-1088, (2016)

[2]

Akbarzadeh A., Rezaei-Sadabady R., Davaran S., Joo S.W., Zarghami N., Hanifehpour Y., Et al., Liposome: classification, preparation, and applications, Nanoscale Res Lett, 8, 1, (2013)

[3]

Alberts B., Johnson A., Lewis J., Raff M., Roberts K., Walter P., Principles of membrane transport, Molecular biology of the cell, 4th edn. Garland Science, (2002)

[4]

Arnold A.E., Czupiel P., Shoichet M., Engineered polymeric nanoparticles to guide the cellular internalization and trafficking of small interfering ribonucleic acids, J Control Release, 259, pp. 3-15, (2017)

[5]

Badve S., Dabbs D.J., Schnitt S.J., Baehner F.L., Decker T., Eusebi V., Et al., Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists, Mod Pathol, 24, 2, pp. 157-167, (2011)

[6]

Bae S.Y., Kim S., Lee J.H., Lee H.C., Lee S.K., Kil W.H., Et al., Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer, BMC Cancer, 15, (2015)

[7]

Bai M., Shen M., Teng Y., Sun Y., Li F., Zhang X., Et al., Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasound, Oncotarget, 6, 41, pp. 43779-43790, (2015)

[8]

Balazs D.A., Godbey W.T., Liposomes for use in gene delivery, J Drug Deliv, 2011, (2011)

[9]

Bannunah A.M., Vllasaliu D., Lord J., Stolnik S., Mechanisms of nanoparticle internalization and transport across an intestinal epithelial cell model: effect of size and surface charge, Mol Pharm, 11, 12, pp. 4363-4373, (2014)

[10]

Bedi D., Gillespie J.W., Petrenko V.A., Ebner A., Leitner M., Hinterdorfer P., Et al., Targeted delivery of siRNA into breast cancer cells via phage fusion proteins, Mol Pharm, 10, 2, pp. 551-559, (2013)

← 1 2 3 4 5 6 7 8 9 10 →